Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX versus KEFUROX IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX versus KEFUROX IN PLASTIC CONTAINER.
CEFIZOX vs KEFUROX IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefizox (ceftizoxime) is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 and PBP-1a/1b, leading to inhibition of transpeptidase activity and autolysin-mediated cell death.
1-2 g IV/IM every 8-12 hours; maximum 12 g/day for severe infections.
750 mg to 1.5 g IV every 8 hours; for severe infections, up to 3 g IV every 8 hours.
None Documented
None Documented
1.7-1.9 hours in adults; prolonged to 15-25 hours in severe renal impairment (CrCl <10 mL/min)
1.2-1.6 hours in adults with normal renal function. Extended to 15-22 hours in end-stage renal disease.
Primarily renal (90-95% unchanged via glomerular filtration and tubular secretion); biliary (<1%); fecal (minimal)
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: <2% excreted in bile. Fecal: <1%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic